Rüsselsheim, Germany

Klaus Ehrlich


Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Rüsselsheim, DE (2002 - 2004)
  • Russelsheim, DE (2005)

Company Filing History:


Years Active: 2002-2005

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Klaus Ehrlich: Innovator in Pharmaceutical Development

Introduction

Klaus Ehrlich is a notable inventor based in Rüsselsheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative research and development efforts. With a total of 3 patents to his name, Ehrlich has established himself as a key figure in the industry.

Latest Patents

Ehrlich's latest patents include groundbreaking work on Coniosulfides and their derivatives, which are compounds formed during fermentation by the microorganism Udagawa, DSM 13856. This invention not only details the compounds but also outlines processes for their preparation and their potential use as pharmaceuticals. Additionally, he has developed a process for producing a pharmaceutical aimed at treating and preventing degenerative neuropathies, including Alzheimer's disease. Another significant patent involves Cyclipostins, which includes processes for their preparation and applications in the pharmaceutical field.

Career Highlights

Klaus Ehrlich is currently associated with Aventis Pharma Deutschland GmbH, where he continues to push the boundaries of pharmaceutical innovation. His work has been instrumental in advancing the understanding and application of various compounds in medical treatments.

Collaborations

Throughout his career, Ehrlich has collaborated with esteemed colleagues such as Laszlo Vertesy and Michael Kurz. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Klaus Ehrlich's contributions to pharmaceutical innovation are noteworthy, and his patents reflect a commitment to advancing medical science. His work continues to impact the field positively, paving the way for future developments in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…